WANY
LCTX icon

Wealthspire Advisors (New York)’s Lineage Cell Therapeutics LCTX Stock Holding History

Wealthspire Advisors (New York)’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$105K Buy
+80,088
New +$111K ﹤0.01% 1220
2025
Q4 		– Sell
-88
Closed -$149 – 2059
2025
Q3 		$149 Buy
+88
New +$104 ﹤0.01% 2973

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Wealthspire Advisors (New York)'s LCTX Position: Q2 2026 in Review

Wealthspire Advisors (New York) opened a new position in Lineage Cell Therapeutics (LCTX) in Q2 2026: 80,088 shares worth $105K. The stake represents ﹤0.01% of the portfolio and ranks #1220 among its holdings. This is a return to the name: Wealthspire Advisors (New York) previously reported a position in LCTX as recently as Q3 2025.

Wealthspire Advisors (New York) first reported a position in LCTX in Q3 2025 and has held it in 2 quarters since. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

  • Wealthspire Advisors (New York) held 80,088 shares of Lineage Cell Therapeutics worth $105K as of Q2 2026.
  • Lineage Cell Therapeutics was a new Wealthspire Advisors (New York) position in Q2 2026.
  • Lineage Cell Therapeutics made up ﹤0.01% of Wealthspire Advisors (New York)'s portfolio in Q2 2026, its #1220 holding.
  • Wealthspire Advisors (New York) first reported a position in Lineage Cell Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • 132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on Wealthspire Advisors (New York)'s 13F filing for Q2 2026, filed 11 Aug 2026.